BACKGROUND The impact of different cytomegalovirus (HCMV) glycoprotein B (gB) genotypes on pathogenesis remains controversial. OBJECTIVES To investigate the effect of gB genotypes either as single infections or as part of multiple infections on the early kinetics of response to ganciclovir therapy. METHODS Patients (n=239) enrolled in a study of intravenous ganciclovir or valganciclovir for...

Little is known about cytomegalovirus (CMV) infection after face transplantation, since only two of the 11 cases of face transplantation reported worldwide have documented a CMV infection after transplantation. Herein, we present the first report of a composite-tissue face allotransplant recipient at high risk for CMV infection (D(+)/R(-) [CMV serpositive donor positive/CMV seronegative recepto...

Cytomegalovirus (CMV) is the most common opportunistic pathogen affecting renal transplant recipients, especially in first months. CMV-seropositive recipients (CMV R+) are at intermediate risk for CMV disease, but this enhanced among R+ receiving T-cell depleting induction, compared to non-depleting induction. In second group, data favor of prophylactic antiviral treatment with valganciclovir r...